Talaie Tara, DiChiacchio Laura, Prasad Nikhil K, Pasrija Chetan, Julliard Walker, Kaczorowski David J, Zhao Yunge, Lau Christine L
Department of Surgery, University of Maryland Medical Center, Baltimore, MD.
Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA.
Transplant Direct. 2021 Jan 7;7(2):e652. doi: 10.1097/TXD.0000000000001104. eCollection 2021 Feb.
Lung ischemia-reperfusion injury (LIRI) and primary graft dysfunction are leading causes of morbidity and mortality among lung transplant recipients. Although extensive research endeavors have been undertaken, few preventative and therapeutic treatments have emerged for clinical use. Novel strategies are still needed to improve outcomes after lung transplantation. In this review, we discuss the underlying mechanisms of transplanted LIRI, potential modifiable targets, current practices, and areas of ongoing investigation to reduce LIRI and primary graft dysfunction in lung transplant recipients.
肺缺血再灌注损伤（LIRI）和原发性移植肺功能障碍是肺移植受者发病和死亡的主要原因。尽管已经进行了广泛的研究，但很少有预防性和治疗性的治疗方法可供临床使用。仍需要新的策略来改善肺移植后的结果。在这篇综述中，我们讨论了移植性LIRI的潜在机制、潜在的可调节靶点、当前的做法以及正在进行的研究领域，以减少肺移植受者的LIRI和原发性移植肺功能障碍。
